Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022009163 - COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Publication Number WO/2022/009163
Publication Date 13.01.2022
International Application No. PCT/IB2021/056177
International Filing Date 09.07.2021
IPC
A61K 31/497 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965Non-condensed pyrazines
497containing further heterocyclic rings
A61K 31/70 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61P 13/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
Applicants
  • ASTRAZENECA AB [SE]/[SE]
Inventors
  • GREASLEY, Peter
  • AHLSTRÖM, Christine
  • SKRTIC, Stanko
  • MENZIES, Robert
Agents
  • LEESE, Mathew
Priority Data
63/050,14710.07.2020US
63/196,79304.06.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE
(FR) COMBINAISON DE ZIBOTENTAN ET DE DAPAGLIFLOZINE POUR LE TRAITEMENT D'UNE MALADIE RÉNALE CHRONIQUE
Abstract
(EN) The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
(FR) La présente invention concerne l'antagoniste du récepteur de l'endothéline (ERA), le zibotentan en combinaison avec l'inhibiteur du cotransporteur du sodium-glucose de type 2 (SGLT-2), la dapagliflozine pour une utilisation dans le traitement de certaines maladies liées à l'endothéline.
Latest bibliographic data on file with the International Bureau